Unmodified autologous stem cells at point of care for chronic myocardial infarction : = Unmodified autologous stem cells at point of care for chronic myocardial infarction
BACKGROUND Numerous studies investigated cell-based therapies for myocardial infarction(MI). The conflicting results of these studies have established the need for developing innovative approaches for applying cell-based therapy for MI.Experimental studies on animal models demonstrated the potential of fresh,uncultured, unmodified, autologous adipose-derived regenerative cells(UAADRCs) for treating acute MI. In contrast, studies on the treatment of chronic MI(CMI; > 4 wk post-MI) with UA-ADRCs have not been published so far. Among several methods for delivering cells to the myocardium, retrograde delivery into a temporarily blocked coronary vein has recently been demonstrated as an effective option.AIM To test the hypothesis that in experimentally-induced chronic myocardial infarction(CMI; > 4 wk post-MI) in pigs, retrograde delivery of fresh, uncultured,unmodified, autologous adipose-derived regenerative cells(UA-ADRCs) into a temporarily blocked coronary vein improves cardiac function and structure.METHODS The left anterior descending(LAD) coronary artery of pigs was blocked for 180 min at time point T0. Then, either 18 × 106 UA-ADRCs prepared at "point of care"or saline as control were retrogradely delivered via an over-the-wire balloon catheter placed in the temporarily blocked LAD vein 4 wk after T0(T1). Effects of cells or saline were assessed by cardiac magnetic resonance(CMR) imaging, late gadolinium enhancement CMR imaging, and post mortem histologic analysis 10 wk after T0(T2).RESULTS Unlike the delivery of saline, delivery of UA-ADRCs demonstrated statistically significant improvements in cardiac function and structure at T2 compared to T1(all values given as mean ± SE): Increased mean LVEF(UA-ADRCs group: 34.3%± 2.9% at T1 vs 40.4 ± 2.6% at T2, P = 0.037; saline group: 37.8% ± 2.6% at T1 vs36.2% ± 2.4% at T2, P > 0.999), increased mean cardiac output(UA-ADRCs group:2.7 ± 0.2 L/min at T1 vs 3.8 ± 0.2 L/min at T2, P = 0.002; saline group: 3.4 ± 0.3 L/min at T1 vs 3.6 ± 0.3 L/min at T2, P = 0.798), increased mean mass of the left ventricle(UA-ADRCs group: 55.3 ± 5.0 g at T1 vs 71.3 ± 4.5 g at T2, P < 0.001;saline group: 63.2 ± 3.4 g at T1 vs 68.4 ± 4.0 g at T2, P = 0.321) and reduced mean relative amount of scar volume of the left ventricular wall(UA-ADRCs group:20.9% ± 2.3% at T1 vs 16.6% ± 1.2% at T2, P = 0.042; saline group: 17.6% ± 1.4% at T1 vs 22.7% ± 1.8% at T2, P = 0.022).CONCLUSION Retrograde cell delivery of UA-ADRCs in a porcine model for the study of CMI significantly improved myocardial function, increased myocardial mass and reduced the formation of scar tissue..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-10-26 2019 |
|---|---|
| Erschienen: |
2019-10-26 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
World Journal of Stem Cells = 世界干细胞杂志(电子版)(英文版) - (2019), 10 vom: 26. Okt., Seite 831-858 Original Letters: Enthalten in (DE-627)CAJ467599610 (DE-627)CAJ467599610 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Unmodified autologous stem cells at point of care for chronic myocardial infarction |
|---|
| Beteiligte Personen: |
Alexander Haenel [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Anmerkungen: |
Author info:Alexander Haenel;Mohamad Ghosn;Tahereh Karimi;Jody Vykoukal;Dipan Shah;Miguel Valderrabano;Daryl G Schulz;Albert Raizner;Christoph Schmitz;Eckhard U Alt;Heart and Vascular Institute, Department of Medicine, Tulane University Health Science Center;The Methodist Hospital Research Institute;Department of Radiology and Nuclear Medicine, University Hospital Schleswig-Holstein;Houston Methodist DeBakey Heart and Vascular Center;Department of Translational Molecular Pathology, MD Anderson Cancer Center, The University of Texas;Institute of Anatomy, Faculty of Medicine, LMU Munich;Isar Klinikum Munich |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ643952608 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ643952608 | ||
| 003 | DE-627 | ||
| 005 | 20230318180455.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230103s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ643952608 | ||
| 035 | |a (SBB-XA)CAJ_WJSC201910008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R542.22 |2 clc | ||
| 100 | 0 | |a Alexander Haenel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unmodified autologous stem cells at point of care for chronic myocardial infarction |b = Unmodified autologous stem cells at point of care for chronic myocardial infarction |
| 246 | 3 | 1 | |a Unmodified autologous stem cells at point of care for chronic myocardial infarction |
| 264 | 1 | |c 2019-10-26 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:Alexander Haenel;Mohamad Ghosn;Tahereh Karimi;Jody Vykoukal;Dipan Shah;Miguel Valderrabano;Daryl G Schulz;Albert Raizner;Christoph Schmitz;Eckhard U Alt;Heart and Vascular Institute, Department of Medicine, Tulane University Health Science Center;The Methodist Hospital Research Institute;Department of Radiology and Nuclear Medicine, University Hospital Schleswig-Holstein;Houston Methodist DeBakey Heart and Vascular Center;Department of Translational Molecular Pathology, MD Anderson Cancer Center, The University of Texas;Institute of Anatomy, Faculty of Medicine, LMU Munich;Isar Klinikum Munich | ||
| 520 | |a BACKGROUND Numerous studies investigated cell-based therapies for myocardial infarction(MI). The conflicting results of these studies have established the need for developing innovative approaches for applying cell-based therapy for MI.Experimental studies on animal models demonstrated the potential of fresh,uncultured, unmodified, autologous adipose-derived regenerative cells(UAADRCs) for treating acute MI. In contrast, studies on the treatment of chronic MI(CMI; > 4 wk post-MI) with UA-ADRCs have not been published so far. Among several methods for delivering cells to the myocardium, retrograde delivery into a temporarily blocked coronary vein has recently been demonstrated as an effective option.AIM To test the hypothesis that in experimentally-induced chronic myocardial infarction(CMI; > 4 wk post-MI) in pigs, retrograde delivery of fresh, uncultured,unmodified, autologous adipose-derived regenerative cells(UA-ADRCs) into a temporarily blocked coronary vein improves cardiac function and structure.METHODS The left anterior descending(LAD) coronary artery of pigs was blocked for 180 min at time point T0. Then, either 18 × 106 UA-ADRCs prepared at "point of care"or saline as control were retrogradely delivered via an over-the-wire balloon catheter placed in the temporarily blocked LAD vein 4 wk after T0(T1). Effects of cells or saline were assessed by cardiac magnetic resonance(CMR) imaging, late gadolinium enhancement CMR imaging, and post mortem histologic analysis 10 wk after T0(T2).RESULTS Unlike the delivery of saline, delivery of UA-ADRCs demonstrated statistically significant improvements in cardiac function and structure at T2 compared to T1(all values given as mean ± SE): Increased mean LVEF(UA-ADRCs group: 34.3%± 2.9% at T1 vs 40.4 ± 2.6% at T2, P = 0.037; saline group: 37.8% ± 2.6% at T1 vs36.2% ± 2.4% at T2, P > 0.999), increased mean cardiac output(UA-ADRCs group:2.7 ± 0.2 L/min at T1 vs 3.8 ± 0.2 L/min at T2, P = 0.002; saline group: 3.4 ± 0.3 L/min at T1 vs 3.6 ± 0.3 L/min at T2, P = 0.798), increased mean mass of the left ventricle(UA-ADRCs group: 55.3 ± 5.0 g at T1 vs 71.3 ± 4.5 g at T2, P < 0.001;saline group: 63.2 ± 3.4 g at T1 vs 68.4 ± 4.0 g at T2, P = 0.321) and reduced mean relative amount of scar volume of the left ventricular wall(UA-ADRCs group:20.9% ± 2.3% at T1 vs 16.6% ± 1.2% at T2, P = 0.042; saline group: 17.6% ± 1.4% at T1 vs 22.7% ± 1.8% at T2, P = 0.022).CONCLUSION Retrograde cell delivery of UA-ADRCs in a porcine model for the study of CMI significantly improved myocardial function, increased myocardial mass and reduced the formation of scar tissue. | ||
| 610 | 2 | 4 | |a Heart and Vascular Institute, Department of Medicine, Tulane University Health Science Center |
| 610 | 2 | 4 | |a The Methodist Hospital Research Institute |
| 610 | 2 | 4 | |a Department of Radiology and Nuclear Medicine, University Hospital Schleswig-Holstein |
| 610 | 2 | 4 | |a Houston Methodist DeBakey Heart and Vascular Center |
| 610 | 2 | 4 | |a Department of Translational Molecular Pathology, MD Anderson Cancer Center, The University of Texas |
| 610 | 2 | 4 | |a Institute of Anatomy, Faculty of Medicine, LMU Munich |
| 610 | 2 | 4 | |a Isar Klinikum Munich |
| 650 | 4 | |a 心脏、血管（循环系）疾病 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Cardiovascular System Disease | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a Adipose tissue-derived regenerative cells | |
| 650 | 4 | |a Chronic myocardial infarction | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Stem cells | |
| 650 | 4 | |a Translational medicine | |
| 650 | 4 | |a Point of care cell therapy | |
| 700 | 0 | |a Mohamad Ghosn |4 oth | |
| 700 | 0 | |a Tahereh Karimi |4 oth | |
| 700 | 0 | |a Jody Vykoukal |4 oth | |
| 700 | 0 | |a Dipan Shah |4 oth | |
| 700 | 0 | |a Miguel Valderrabano |4 oth | |
| 700 | 0 | |a Daryl G Schulz |4 oth | |
| 700 | 0 | |a Albert Raizner |4 oth | |
| 700 | 0 | |a Christoph Schmitz |4 oth | |
| 700 | 0 | |a Eckhard U Alt |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t World Journal of Stem Cells = 世界干细胞杂志(电子版)(英文版) |g (2019), 10 vom: 26. Okt., Seite 831-858 |w (DE-627)CAJ467599610 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:10 |g day:26 |g month:10 |g pages:831-858 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=WJSC201910008 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=WJSC201910008 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |w (DE-627)CAJ467599610 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 10 |b 26 |c 10 |h 831-858 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 10 |b 26 |c 10 |h 831-858 | ||
| 980 | |2 11 |1 01 |x 0001 |b 663457386 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 03-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=WJSC201910008 | ||